HBK Sorce Advisory’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $16.5M | Buy |
17,368
+334
| +2% | +$339K | 0.33% | 30 |
|
|
2025
Q4 | $18M | Sell |
17,034
-365
| -2% | -$349K | 0.41% | 26 |
|
|
2025
Q3 | $14.4M | Buy |
17,399
+396
| +2% | +$295K | 0.36% | 28 |
|
|
2025
Q2 | $13.3M | Sell |
17,003
-26
| -0.2% | -$20.2K | 0.36% | 27 |
|
|
2025
Q1 | $14.1M | Buy |
17,029
+451
| +3% | +$375K | 0.41% | 23 |
|
|
2024
Q4 | $12.8M | Sell |
16,578
-2,281
| -12% | -$1.89M | 0.39% | 26 |
|
|
2024
Q3 | $16.7M | Sell |
18,859
-312
| -2% | -$281K | 0.51% | 20 |
|
|
2024
Q2 | $17.4M | Sell |
19,171
-356
| -2% | -$285K | 0.61% | 19 |
|
|
2024
Q1 | $15.2M | Buy |
19,527
+809
| +4% | +$576K | 0.54% | 22 |
|
|
2023
Q4 | $10.9M | Sell |
18,718
-1,622
| -8% | -$947K | 0.42% | 27 |
|
|
2023
Q3 | $10.9M | Sell |
20,340
-886
| -4% | -$457K | 0.48% | 23 |
|
|
2023
Q2 | $9.95M | Sell |
21,226
-156
| -0.7% | -$65.4K | 0.42% | 25 |
|
|
2023
Q1 | $7.34M | Sell |
21,382
-19,548
| -48% | -$6.59M | 0.33% | 40 |
|
|
2022
Q4 | $15M | Buy |
40,930
+24,445
| +148% | +$8.67M | 0.4% | 37 |
|
|
2022
Q3 | $5.33M | Buy |
16,485
+42
| +0.3% | +$13.3K | 0.36% | 44 |
|
|
2022
Q2 | $5.33M | Sell |
16,443
-4,972
| -23% | -$1.49M | 0.39% | 34 |
|
|
2022
Q1 | $6.13M | Sell |
21,415
-1,251
| -6% | -$322K | 0.34% | 44 |
|
|
2021
Q4 | $6.26M | Buy |
22,666
+1,072
| +5% | +$272K | 0.32% | 45 |
|
|
2021
Q3 | $4.99M | Buy |
21,594
+200
| +0.9% | +$49.4K | 0.28% | 51 |
|
|
2021
Q2 | $4.91M | Buy |
21,394
+1,573
| +8% | +$316K | 0.27% | 52 |
|
|
2021
Q1 | $3.7M | Sell |
19,821
-2,512
| -11% | -$491K | 0.22% | 68 |
|
|
2020
Q4 | $3.77M | Sell |
22,333
-397
| -2% | -$59.3K | 0.23% | 56 |
|
|
2020
Q3 | $3.37M | Sell |
22,730
-1,632
| -7% | -$253K | 0.24% | 56 |
|
|
2020
Q2 | $4M | Buy |
24,362
+781
| +3% | +$120K | 0.3% | 51 |
|
|
2020
Q1 | $3.27M | Sell |
23,581
-101
| -0.4% | -$13.9K | 0.32% | 46 |
|
|
2019
Q4 | $3.11M | Buy |
23,682
+63
| +0.3% | +$7.3K | 0.27% | 68 |
|
|
2019
Q3 | $2.64M | Buy |
23,619
+3,968
| +20% | +$442K | 0.25% | 79 |
|
|
2019
Q2 | $2.18M | Sell |
19,651
-183
| -0.9% | -$21.6K | 0.21% | 91 |
|
|
2019
Q1 | $2.57M | Buy |
19,834
+172
| +0.9% | +$20.9K | 0.26% | 84 |
|
|
2018
Q4 | $2.27M | Buy |
19,662
+479
| +2% | +$53.5K | 0.26% | 83 |
|
|
2018
Q3 | $2.06M | Sell |
19,183
-107
| -0.6% | -$10.7K | 0.23% | 75 |
|
|
2018
Q2 | $1.65M | Sell |
19,290
-122
| -0.6% | -$10K | 0.19% | 88 |
|
|
2018
Q1 | $1.5M | Sell |
19,412
-2,381
| -11% | -$192K | 0.19% | 89 |
|
|
2017
Q4 | $1.84M | Buy |
21,793
+6,840
| +46% | +$582K | 0.22% | 84 |
|
|
2017
Q3 | $1.28M | Buy |
14,953
+360
| +2% | +$29.5K | 0.19% | 81 |
|
|
2017
Q2 | $1.2M | Buy |
+14,593
| New | +$1.19M | 0.19% | 80 |
|
|
2017
Q1 | – | Sell |
-14,635
| Closed | -$1.17M | – | 368 |
|
|
2016
Q4 | $1.08M | Buy |
14,635
+603
| +4% | +$44.9K | 0.19% | 88 |
|
|
2016
Q3 | $1.13M | Buy |
14,032
+1,752
| +14% | +$140K | 0.22% | 73 |
|
|
2016
Q2 | $967K | Buy |
12,280
+5,022
| +69% | +$378K | 0.21% | 80 |
|
|
2016
Q1 | $523K | Buy |
7,258
+276
| +4% | +$20.9K | 0.12% | 124 |
|
|
2015
Q4 | $588K | Buy |
6,982
+230
| +3% | +$19.1K | 0.15% | 99 |
|
|
2015
Q3 | $565K | Buy |
6,752
+380
| +6% | +$32.1K | 0.18% | 88 |
|
|
2015
Q2 | $532K | Sell |
6,372
-285
| -4% | -$21.7K | 0.18% | 98 |
|
|
2015
Q1 | $484K | Buy |
6,657
+2,524
| +61% | +$180K | 0.16% | 97 |
|
|
2014
Q4 | $285K | Buy |
4,133
+349
| +9% | +$23.6K | 0.1% | 141 |
|
|
2014
Q3 | $245K | Buy |
+3,784
| New | +$240K | 0.09% | 149 |
|
Other funds holding LLY
VCM
VPM
HBK Sorce Advisory's LLY Position: Q1 2026 in Review
HBK Sorce Advisory increased its Eli Lilly (LLY) stake by 2% in Q1 2026, buying an estimated $339K and bringing the position to 17,368 shares worth $16.5M. The position accounts for 0.33% of the portfolio, ranked #30.
HBK Sorce Advisory first reported a position in LLY in Q3 2014 and has held it in 46 quarters since. The position peaked at $18M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- HBK Sorce Advisory held 17,368 shares of Eli Lilly worth $16.5M as of Q1 2026.
- HBK Sorce Advisory bought 334 Eli Lilly shares in Q1 2026, an estimated $339K.
- Eli Lilly made up 0.33% of HBK Sorce Advisory's portfolio in Q1 2026, its #30 holding.
- HBK Sorce Advisory first reported a position in Eli Lilly in Q3 2014 and has held it in 46 quarters since.
- HBK Sorce Advisory's Eli Lilly position peaked at $18M in Q4 2025.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on HBK Sorce Advisory's 13F filing for Q1 2026, filed 11 May 2026.